CN101094846A - 用作mglur3受体拮抗剂的1－(杂)芳基－3－氨基－吡咯烷衍生物 - Google Patents

用作mglur3受体拮抗剂的1－(杂)芳基－3－氨基－吡咯烷衍生物 Download PDF

Info

Publication number
CN101094846A
CN101094846A CNA200580035313XA CN200580035313A CN101094846A CN 101094846 A CN101094846 A CN 101094846A CN A200580035313X A CNA200580035313X A CN A200580035313XA CN 200580035313 A CN200580035313 A CN 200580035313A CN 101094846 A CN101094846 A CN 101094846A
Authority
CN
China
Prior art keywords
amine
compound
mmol
tetramethyleneimine
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200580035313XA
Other languages
English (en)
Chinese (zh)
Inventor
T·C·布里顿
V·德林格尔
C·P·德尔
B·A·德雷斯曼
J·K·迈尔斯
E·S·尼森鲍姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN101094846A publication Critical patent/CN101094846A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/41—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrogenolysis or reduction of carboxylic groups or functional derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CNA200580035313XA 2004-10-18 2005-10-13 用作mglur3受体拮抗剂的1－(杂)芳基－3－氨基－吡咯烷衍生物 Pending CN101094846A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61978904P 2004-10-18 2004-10-18
US60/619,789 2004-10-18

Publications (1)

Publication Number Publication Date
CN101094846A true CN101094846A (zh) 2007-12-26

Family

ID=35787981

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200580035313XA Pending CN101094846A (zh) 2004-10-18 2005-10-13 用作mglur3受体拮抗剂的1－(杂)芳基－3－氨基－吡咯烷衍生物

Country Status (12)

Country Link
US (1) US7868014B2 (enExample)
EP (1) EP1805165B1 (enExample)
JP (1) JP5188807B2 (enExample)
CN (1) CN101094846A (enExample)
AT (1) ATE452130T1 (enExample)
AU (1) AU2005295860A1 (enExample)
BR (1) BRPI0516602A (enExample)
CA (1) CA2584422A1 (enExample)
DE (1) DE602005018381D1 (enExample)
ES (1) ES2336130T3 (enExample)
MX (1) MX2007004661A (enExample)
WO (1) WO2006044454A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102203077B (zh) * 2008-11-04 2014-07-09 默沙东有限责任公司 用于治疗疼痛的(吡咯烷-2-基)苯基衍生物
CN113024412A (zh) * 2021-03-23 2021-06-25 上海立科化学科技有限公司 2,4,6-三氯苯腈的制备方法
CN114149297A (zh) * 2021-12-07 2022-03-08 北京中医药大学 一种微波辅助的选择性芳基甲醛的绿色合成方法
CN115368283A (zh) * 2022-09-15 2022-11-22 丽水绿氟科技有限公司 一种手性结构或非手性结构的顺式-3-氟-4-羟基吡咯烷及其衍生物的制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1757582T3 (pl) * 2004-05-28 2016-04-29 Mitsubishi Tanabe Pharma Corp Aryloalkiloaminy i sposób ich wytwarzania
FR2928150A1 (fr) 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
EP2145891A1 (en) 2008-07-09 2010-01-20 Vetoquinol S.A. 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
AU2015359352B2 (en) 2014-12-11 2020-07-02 Janssen Pharmaceutica Nv 1,2,4-triazolo(4,3-a)pyridine compounds and their use as positive allosteric modulators of mGluR2 receptors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
US4785119A (en) 1985-10-11 1988-11-15 Tokyo Kasei Kogyo Co., Ltd. 3-aminopyrrolidine compound and process for preparation thereof
UA41251C2 (uk) 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5332817A (en) 1990-01-04 1994-07-26 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles
TW202432B (enExample) 1991-06-21 1993-03-21 Pfizer
WO1995029891A1 (en) * 1994-04-28 1995-11-09 Yamanouchi Pharmaceutical Co., Ltd. N-(3-pyrrolidinyl)benzamide derivative
ES2079323B1 (es) * 1994-06-21 1996-10-16 Vita Invest Sa Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes.
DE19524765A1 (de) 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DK0874625T3 (da) 1996-01-22 2005-06-20 Lilly Co Eli Indanderivater til antipsykotiske præparater
AU1608397A (en) 1996-02-02 1997-08-22 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
US5891889A (en) 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6204292B1 (en) 1997-07-18 2001-03-20 Georgetown University Bicyclic metabotropic glutamate receptor ligands
CA2297906A1 (en) 1997-07-22 1999-02-04 Bret Eugene Huff Pharmaceutical compounds
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
WO1999064396A1 (en) * 1998-06-09 1999-12-16 Neurogen Corporation Substituted 1-aryl-3-benzylaminopyrrolidine: dopamine receptor subtype specific ligands
WO2002091988A2 (en) * 2001-05-10 2002-11-21 Aventis Pharma Deutschland Gmbh Novel processes for the preparation of adenosine compounds and intermediates thereto
AU2003300021A1 (en) * 2002-12-27 2004-07-29 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR100803796B1 (ko) 2003-06-17 2008-02-14 화이자 인코포레이티드 세로토닌 및 노르아드레날린 재흡수 억제제로서의ｎ-피롤리딘-3-일-아미드 유도체
US7348434B2 (en) 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
CA2539335A1 (en) * 2003-10-31 2005-05-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis
PL1757582T3 (pl) * 2004-05-28 2016-04-29 Mitsubishi Tanabe Pharma Corp Aryloalkiloaminy i sposób ich wytwarzania

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102203077B (zh) * 2008-11-04 2014-07-09 默沙东有限责任公司 用于治疗疼痛的(吡咯烷-2-基)苯基衍生物
CN113024412A (zh) * 2021-03-23 2021-06-25 上海立科化学科技有限公司 2,4,6-三氯苯腈的制备方法
CN114149297A (zh) * 2021-12-07 2022-03-08 北京中医药大学 一种微波辅助的选择性芳基甲醛的绿色合成方法
CN115368283A (zh) * 2022-09-15 2022-11-22 丽水绿氟科技有限公司 一种手性结构或非手性结构的顺式-3-氟-4-羟基吡咯烷及其衍生物的制备方法

Also Published As

Publication number Publication date
JP2008516959A (ja) 2008-05-22
EP1805165A1 (en) 2007-07-11
CA2584422A1 (en) 2006-04-27
BRPI0516602A (pt) 2008-09-16
WO2006044454A1 (en) 2006-04-27
DE602005018381D1 (de) 2010-01-28
AU2005295860A1 (en) 2006-04-27
US20080300266A1 (en) 2008-12-04
US7868014B2 (en) 2011-01-11
ATE452130T1 (de) 2010-01-15
ES2336130T3 (es) 2010-04-08
EP1805165B1 (en) 2009-12-16
JP5188807B2 (ja) 2013-04-24
MX2007004661A (es) 2007-06-22

Similar Documents

Publication Publication Date Title
CN101305011B (zh) 吡啶衍生物及其在治疗精神障碍中的用途
CN104703987B (zh) 具有咪唑并吡嗪酮骨架的pde9抑制剂
JP2022505987A (ja) Ｔｙｋ２阻害剤およびその使用
CN114173803A (zh) 氨基酸化合物的剂型和方案
TWI577681B (zh) 咪唑并嗒化合物
DE69108461T2 (de) 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazine.
CN106211770B (zh) 作为γ‑分泌酶调节剂的色烯和1,1A,2,7B‑四氢环丙烷并[c]色烯吡啶并吡嗪二酮
CN102015720A (zh) 神经元烟碱性受体的选择性配体及其应用
CN103781776A (zh) 用作端锚聚合酶抑制剂的新的2-哌啶-1-基-乙酰胺化合物
HK1217945A1 (zh) 作爲pde4亚型抑制剂用於治疗cns和其他病症的氮杂苯并咪唑化合物
EP2094684B1 (en) 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin 2-ones as cb1 receptor modulators
CN101094846A (zh) 用作mglur3受体拮抗剂的1－(杂)芳基－3－氨基－吡咯烷衍生物
CN101874022A (zh) 吲唑丙烯酸酰胺化合物
CN105263924A (zh) Cxcr7受体调节剂
CN103857670B (zh) 2-氧代-哌啶基衍生物
WO2020088390A1 (zh) 作为第四代egfr抑制剂的嘧啶吡唑类化合物
CN100548299C (zh) 兴奋性氨基酸受体拮抗剂
CN101365678A (zh) 可用于治疗h3受体相关病症的h3受体调节剂
CN102245613A (zh) 苯基和杂芳基取代的噻吩并[2，3-d]嘧啶及它们作为腺苷A2a受体拮抗剂的用途
CN117430589A (zh) 2-氨基嘧啶类化合物或其盐及其制备方法和用途
HK40070149A (en) Dosage forms and regimens for amino acid compounds
HK1196605B (en) 2-oxo-piperidinyl derivatives
HK1231481B (zh) 作为γ-分泌酶调节剂的色烯和1，1A，2，7B-四氢环丙烷并[C]色烯吡啶并吡嗪二酮

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20071226